Skip to main content
Premium Trial:

Request an Annual Quote

BD Reports 12-Percent Rise in Fiscal Q3 Sales; R&D, Profit Post Gains

NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal third-quarter revenues rose 11.6 percent as R&D spending climbed 21 percent and profit grew 19 percent.
 
Total receipts for the three months ended June 30 increased to $1.63 billion from $1.46 billion year over year.
 
BD said revenues from its Diagnostics segment grew 15 percent to $492 million, while Biosciences revenue rose 13 percent to $258 million. Revenue from the Medical segment rose 10 percent to $882 million.  
 
R&D spending for the quarter rose to $93 million from $77 million year over year.
 
Profits for the quarter increased to $245 million from $206 million in the year-ago period.
 
The company did not disclose its balance sheet for the period.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.